FDA approves extended storage for ADMA Biologics products
Investing.com | Editor Emilio Ghigini
Published Mar 11, 2024 07:07AM ET
RAMSEY, N.J. and BOCA RATON, Fla. - ADMA Biologics, Inc. (NASDAQ: NASDAQ:ADMA), a biopharmaceutical company, announced today the FDA's approval of its supplemental Biologics License Applications for ASCENIV and BIVIGAM. This approval allows these products to be stored at room temperature (25°C) for up to four weeks at any point during their 36-month shelf life. Previously, this was only permissible during the first 24 months.
The FDA's decision is applicable to all existing lots of ASCENIV and BIVIGAM in the commercial supply chain, as well as future production. The company anticipates that the extended storage conditions will enable better inventory management and ease of administration for healthcare providers, potentially expanding the reach of these products to customers with limited refrigeration capabilities.
ASCENIV and BIVIGAM are intravenous immune globulin products used in the treatment of primary humoral immunodeficiency (PI). The approval for extended ambient storage conditions is effective immediately, with both products available to U.S. healthcare providers.
ADMA Biologics operates an FDA-licensed plasma fractionation facility in Boca Raton, Florida, and through its ADMA BioCenters subsidiary, it also collects source plasma. The company's mission includes the development and marketing of specialty biologics for immune-compromised patients.
This recent regulatory update is based on a press release statement from ADMA Biologics and has not been independently verified. The company holds several U.S. and foreign patents related to its products and product candidates. Further information can be found on the company's website.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.